Calico Life Sciences

Calico is the deepest-pocketed, longest-horizon bet on the fundamental biology of aging, backed by Alphabet and led by a genuine industry legend in Arthur Levinson, former Genentech chairman and CEO. Founded in 2013 as an Alphabet subsidiary rather than a venture-funded startup, Calico is structured to do exactly what conventional biotech cannot — pursue high-risk, decade-timeline aging science insulated from fundraising cycles and quarterly pressure. That patient-capital model produced real translational output: the 2014 AbbVie collaboration generated more than 20 early-stage programs across neurodegeneration and immuno-oncology and advanced three candidates into the clinic, an unusually productive engine for a research-first organization. Calico's basic-science work spans computational and model-organism studies of why organisms age — including foundational research on naked mole-rat and yeast biology — that seeds a proprietary understanding of aging mechanisms few institutions can match. With Alphabet's balance sheet behind it and Levinson's drug-development pedigree steering translation, Calico is positioned to convert aging-biology insight into age-related-disease therapeutics on a timeline that would bankrupt any independent company, and to retain optionality on assets even after a partner exits.